{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:20:08Z","timestamp":1790497208145,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K18351"],"award-info":[{"award-number":["18K18351"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.xphs.2019.06.012","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T04:52:45Z","timestamp":1561092765000},"page":"3218-3224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid\u2013Lipid Conjugate"],"prefix":"10.1016","volume":"108","author":[{"given":"Yu","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nako","family":"Maishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyoshi","family":"Harashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.xphs.2019.06.012_bib1","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1183\/09031936.96.09091932","article-title":"The epidemiology of mesothelioma in historical context","volume":"9","author":"McDonald","year":"1996","journal-title":"Eur Respir J"},{"issue":"36","key":"10.1016\/j.xphs.2019.06.012_bib2","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1200\/JCO.2013.49.9616","article-title":"Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma","volume":"31","author":"Chirieac","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.xphs.2019.06.012_bib3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2105\/AJPH.2012.300928","article-title":"Analyses of radiation and mesothelioma in the US transuranium and uranium registries","volume":"103","author":"Gibb","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.xphs.2019.06.012_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jfma.2018.07.013","article-title":"Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: a prediction of incidence in the next 30 years","volume":"118","author":"Lin","year":"2019","journal-title":"J\u00a0Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.012_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and treatment of cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.xphs.2019.06.012_bib6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.xphs.2019.06.012_bib7","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2147\/OTT.S113598","article-title":"Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date","volume":"10","author":"Levin","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"3","key":"10.1016\/j.xphs.2019.06.012_bib8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.xphs.2019.06.012_bib9","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1016\/j.cllc.2018.05.001","article-title":"A\u00a0phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol","volume":"19","author":"Fujimoto","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"9","key":"10.1016\/j.xphs.2019.06.012_bib10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.2174\/1871520617666170102151918","article-title":"Immune checkpoints aberrations and malignant mesothelioma: assessment of prognostic value and evaluation of therapeutic potentials","volume":"17","author":"Mohamed","year":"2017","journal-title":"Anticancer Agents Med Chem"},{"issue":"14","key":"10.1016\/j.xphs.2019.06.012_bib11","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.xphs.2019.06.012_bib12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.21037\/tlcr.2018.04.10","article-title":"Current chemotherapy strategies in malignant pleural mesothelioma","volume":"7","author":"de Gooijer","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"10.1016\/j.xphs.2019.06.012_bib13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.21037\/tlcr.2018.10.02","article-title":"Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations","volume":"7","author":"De Bondt","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.012_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijpharm.2017.11.010","article-title":"Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption","volume":"536","author":"Yamamoto","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2019.06.012_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2017.02.010","article-title":"Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles","volume":"251","author":"Yamamoto","year":"2017","journal-title":"J\u00a0Control Release"},{"issue":"25","key":"10.1016\/j.xphs.2019.06.012_bib16","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1016\/j.biomaterials.2014.04.087","article-title":"An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells","volume":"35","author":"Ara","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.xphs.2019.06.012_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2013.10.003","article-title":"RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system","volume":"173","author":"Sakurai","year":"2014","journal-title":"J\u00a0Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.012_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1517\/17425247.2015.955847","article-title":"Advances in an active and passive targeting to tumor and adipose tissues","volume":"12","author":"Sakurai","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"issue":"Pt B","key":"10.1016\/j.xphs.2019.06.012_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.addr.2015.11.008","article-title":"Heterogeneity of tumor endothelial cells and drug delivery","volume":"99","author":"Hida","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"10.1016\/j.xphs.2019.06.012_bib20","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/mt.2016.178","article-title":"Remodeling of the extracellular matrix by endothelial cell-targeting siRNA improves the EPR-based delivery of 100 nm particles","volume":"24","author":"Sakurai","year":"2016","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2019.06.012_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acsnano.7b08051","article-title":"Nanoplatform assembled from a CD44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells","volume":"12","author":"Lv","year":"2018","journal-title":"ACS Nano"},{"issue":"35","key":"10.1016\/j.xphs.2019.06.012_bib22","doi-asserted-by":"crossref","first-page":"26967","DOI":"10.1016\/S0021-9258(19)61467-5","article-title":"Hyaluronan binding by cell surface CD44","volume":"275","author":"Lesley","year":"2000","journal-title":"J\u00a0Biol Chem"},{"issue":"51","key":"10.1016\/j.xphs.2019.06.012_bib23","doi-asserted-by":"crossref","first-page":"43094","DOI":"10.1074\/jbc.M112.349209","article-title":"The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering","volume":"287","author":"Yang","year":"2012","journal-title":"J\u00a0Biol Chem"},{"issue":"8827","key":"10.1016\/j.xphs.2019.06.012_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0140-6736(92)93077-Z","article-title":"Significance of CD44 gene products for cancer diagnosis and disease evaluation","volume":"340","author":"Matsumura","year":"1992","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.012_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12931-017-0546-5","article-title":"CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives","volume":"18","author":"Cortes-Dericks","year":"2017","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.xphs.2019.06.012_bib26","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/1097-0142(19940301)73:5<1406::AID-CNCR2820730515>3.0.CO;2-I","article-title":"The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods","volume":"73","author":"Martensson","year":"1994","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.012_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jconrel.2008.07.006","article-title":"An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor","volume":"131","author":"Chono","year":"2008","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2019.06.012_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12951-015-0088-2","article-title":"Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells","volume":"13","author":"Maiolino","year":"2015","journal-title":"J\u00a0Nanobiotechnology"},{"issue":"1-2","key":"10.1016\/j.xphs.2019.06.012_bib29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ijpharm.2014.11.012","article-title":"Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance","volume":"477","author":"Ran","year":"2014","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2019.06.012_bib30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1021\/mp800215d","article-title":"Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells","volume":"6","author":"Surace","year":"2009","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2019.06.012_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.canlet.2012.08.024","article-title":"Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells","volume":"334","author":"Landesman-Milo","year":"2013","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.xphs.2019.06.012_bib32","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/nn506248s","article-title":"Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles","volume":"9","author":"Cohen","year":"2015","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.xphs.2019.06.012_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nsmb1201","article-title":"Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction","volume":"14","author":"Banerji","year":"2007","journal-title":"Nat Struct Mol Biol"},{"issue":"3 Pt A","key":"10.1016\/j.xphs.2019.06.012_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejpb.2013.06.003","article-title":"Hyaluronic acid-coated liposomes for active targeting of gemcitabine","volume":"85","author":"Arpicco","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.012_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2013.07.020","article-title":"Enhancement of in\u00a0vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1\u03b1-MUC1 pathway","volume":"339","author":"Goudarzi","year":"2013","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.012_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2220\/biomedres.34.13","article-title":"Hypoxia affects in\u00a0vitro growth of newly established cell lines from patients with malignant pleural mesothelioma","volume":"34","author":"Goudarzi","year":"2013","journal-title":"Biomed Res"},{"issue":"5","key":"10.1016\/j.xphs.2019.06.012_bib37","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3390\/ijms19051361","article-title":"Antimalarial activity of orally administered curcumin incorporated in Eudragit\u00ae-containing liposomes","volume":"19","author":"Mart\u00ed Coma-Cros","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.xphs.2019.06.012_bib38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.nano.2017.12.003","article-title":"PEGylated hyaluronic acid-coated liposome for enhanced in\u00a0vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure","volume":"14","author":"Mo","year":"2018","journal-title":"Nanomedicine"},{"issue":"1-2","key":"10.1016\/j.xphs.2019.06.012_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijpharm.2010.05.002","article-title":"Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake","volume":"396","author":"Takara","year":"2010","journal-title":"Int J Pharm"},{"issue":"26","key":"10.1016\/j.xphs.2019.06.012_bib40","doi-asserted-by":"crossref","first-page":"8982","DOI":"10.1039\/C7NR01020F","article-title":"Can dual-ligand targeting enhance cellular uptake of nanoparticles?","volume":"9","author":"Xia","year":"2017","journal-title":"Nanoscale"},{"issue":"3","key":"10.1016\/j.xphs.2019.06.012_bib41","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.bjc.6600118","article-title":"Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma","volume":"86","author":"van Haarst","year":"2002","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.xphs.2019.06.012_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2011.03.014","article-title":"Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes","volume":"152","author":"Xiang","year":"2011","journal-title":"J\u00a0Control Release"},{"issue":"6","key":"10.1016\/j.xphs.2019.06.012_bib43","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1248\/bpb.b13-00059","article-title":"The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors","volume":"36","author":"Hatakeyama","year":"2013","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.012_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2010.04.028","article-title":"Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in\u00a0vitro cytotoxic activity on tumor cells","volume":"146","author":"Shmeeda","year":"2010","journal-title":"J\u00a0Control Release"},{"issue":"11","key":"10.1016\/j.xphs.2019.06.012_bib45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.21037\/atm.2017.03.78","article-title":"Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma","volume":"5","author":"Okabe","year":"2017","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.xphs.2019.06.012_bib46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.semtcvs.2008.11.002","article-title":"Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma","volume":"20","author":"Mujoomdar","year":"2008","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"10","key":"10.1016\/j.xphs.2019.06.012_bib47","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.2005.04.6813","article-title":"Phase I to II study of pleurectomy\/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma","volume":"24","author":"Richards","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.xphs.2019.06.012_bib48","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1021\/acsnano.6b00900","article-title":"Nanomedicines eradicating cancer stem-like cells in\u00a0vivo by pH-triggered intracellular cooperative action of loaded drugs","volume":"10","author":"Kinoh","year":"2016","journal-title":"ACS Nano"},{"issue":"Pt A","key":"10.1016\/j.xphs.2019.06.012_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2015.10.019","article-title":"Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed","volume":"220","author":"Ando","year":"2015","journal-title":"J\u00a0Control Release"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491930382X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491930382X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:28:13Z","timestamp":1758360493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235491930382X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S002235491930382X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2019.06.012","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid\u2013Lipid Conjugate","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2019.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}